{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-057710","form_type":"8-K","ticker":"NTRA","cik":"0001604821","company_name":"Natera, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.630362+00:00","generated_at":"2026-06-15T09:12:54.056148+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Natera Q1 revenue $241.8M (+24.5% YoY), raises 2023 revenue guidance to $995M-$1.015B","bullets":["Total revenue $241.8M (+24.5% YoY); product revenue $237.8M (+25.2% YoY).","Tests processed 626,200 (+28% YoY); oncology tests 71,000 (+102% YoY).","Net loss $136.9M ($1.23/share) vs $138.6M ($1.45) in prior year; loss per share improved.","Raised 2023 revenue guidance to $995M-$1.015B from prior $990M-$1.0B; gross margin guidance unchanged at 41%-44%.","Secured Medicare coverage for Prospera heart transplant test and first commercial coverage for Signatera (Blue Shield CA)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-057710","json":"https://secwatch.observer/filing/0001104659-23-057710.json","markdown":"https://secwatch.observer/filing/0001104659-23-057710.md","text":"https://secwatch.observer/filing/0001104659-23-057710.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604821/000110465923057710/0001104659-23-057710-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604821/000110465923057710/tm2314862d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:12:54.056148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a0ed467ea0c19ed632e9b81595e2f9e4e620f316","claim":"Natera, Inc. reported first quarter ended March 31, 2023 results: revenue $241.8 million, net income net loss of $136.9 million, EPS ($1.23) per diluted share. Guidance raised.","evidence_excerpt":"in cell-free DNA testing , today reported financial results for the first quarter ended March 31, 2023. Recent Strategic and Financial Highlights ● Generated total revenues of $241.8 million in the first quarter of 2023, compared to $194.1 million in the first quarter of 2022, an increase of 24.5%. Product revenues grew 25.2% over the same period. ● Processed","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604821/000110465923057710/0001104659-23-057710-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$241.8 million"},{"label":"Net income","value":"net loss of $136.9 million"},{"label":"EPS","value":"($1.23) per diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}